0001193125-26-379106 Sample Contracts
EMPLOYMENT AGREEMENTEmployment Agreement • September 2nd, 2026 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on April 7, 2026 (the “Effective Date”) by and between Gregory Oakes (the “Executive”) and Slate Medicines, Inc. (the “Company”).
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS AGREEMENT (INDICATED BY “[***]”) BECAUSE SLATE MEDICINES, INC. HAS DETERMINED SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT BETWEEN...License Agreement • September 2nd, 2026 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
This LICENSE AGREEMENT (this “Agreement”) is entered into as of February 16, 2026 (the “Effective Date”) by and between DARTSBIO PHARMACEUTICALS LTD., a corporation organized and existing under the laws of People’s Republic of China and having a place of business at Third Floor, East Sanwei GMP Building 3, Cuihai Ave, Cuiheng New District Zongshan City, Guangdong Province, China (“Dartsbio”), and SLATE MEDICINES, INC., a corporation organized and existing under the laws of Delaware and having a place of business at c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116 USA (“Slate Medicines”). Dartsbio and Slate Medicines are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS AGREEMENT (INDICATED BY “[***]”) BECAUSE SLATE MEDICINES, INC. HAS DETERMINED SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO...License Agreement • September 2nd, 2026 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (this “First Amendment”) to that certain License Agreement dated as of February 16, 2026 (the “Agreement”) by and between DARTSBIO PHARMACEUTICALS LTD., a corporation organized and existing under the laws of People’s Republic of China and having a place of business at Third Floor, East Sanwei GMP Building 3, Cuihai Ave, Cuiheng New District Zongshan City, Guangdong Province, China (“Dartsbio”), and SLATE MEDICINES, INC., a corporation organized and existing under the laws of Delaware and having a place of business at c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, MA 02116 USA (“Slate Medicines”) is dated as of August 11, 2026 (the “First Amendment Effective Date”). Slate Medicines and Dartsbio are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the respective meanings given to them in the Agreement.
Dated February 17, 2026 SLATE MEDICINES, INC. SLATE MEDICINES UK LIMITED FORBION VENTURES FUND VII COÖPERATIEF U.A AND FORDD VENTURES VII B.V. SHARE EXCHANGE AGREEMENTShare Exchange Agreement • September 2nd, 2026 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
NOW, THEREFORE, in consideration of the covenants and agreements provided in this Agreement and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the parties agree as follows:
EMPLOYMENT AGREEMENTEmployment Agreement • September 2nd, 2026 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on May 18, 2026, by and between John W. Umstead V (the “Executive”) and Slate Medicines, Inc. (the “Company”).
OFFICE LEASEOffice Lease • September 2nd, 2026 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
THIS OFFICE LEASE is executed this 8 day of May, 2026, by and between NORTH HILLS OWNER II LP, a Delaware limited partnership (“Landlord”), and SLATE MEDICINES, INC., a Delaware corporation (“Tenant”).